currently employ close to 500 people across both offshore and onshore locations. The company operates a wide range of work and survey ROVs from its fleet of To subscribe to Press releases from this ...

to provide outstanding solutions for healthcare professionals globally. The Company is headquartered in Oslo, Norway. Further information is available at www.observemedical.com. This information is ...

will commence on 16 June 2025 or as soon as possible after that date. The purpose of the buy-backs is to maintain an efficient capital structure and improve shareholder returns. The programme will ...

Paris, France – June 12, 2025 – Eviden, the Atos Group product brand leading in advanced computing, cybersecurity products, mission-critical systems and vision AI today announces the availability of a ...

1,539 New Shares in the Company at a price per New Share of NOK 5.31681. monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") ...

Orange intends to issue a new series of Euro-denominated hybrid notes and to launch a tender offer on some of its outstanding hybrid notes Orange S.A. (the Company) is today announcing its intention ...

issue amount of USD 200,000,000 and ISIN NO0013063495 on Euronext Oslo Børs. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or ...

The Company confirms that on 11 June 2025 it purchased a total of: (i) 35,044 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 14,745 ordinary shares on the London ...

SEGRO plc ("SEGRO") today announces that it has appointed Susanne Schroeter-Crossan as its new Chief Financial Officer. She will join the Board as an executive director on 1 December 2025, succeeding ...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, ...

1. Jan Jahren, CEO of the Company, has been allocated 1,000,000 Offer Shares for a total amount of NOK 50 million through his wholly owned company, Jan Jahren AS. 2. Christian Wieland, Deputy CEO of ...

will be subject to lock-up of 180 days. Further, the shares held by the Company's CEO and Deputy CEO will be subject to a lock-up of 720 days, following which 1/3 of the shares will be released from ...